Skip to content

A Prospective Randomized Controlled Trial of Modified Bier Block Therapy for the Treatment of Complex Regional Pain Syndrome

A Prospective Randomized Controlled Trial of Modified Bier Block Therapy for the Treatment of Complex Regional Pain Syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114670
Enrollment
Unknown
Registered
2025-12-16
Start date
2024-03-15
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex Regional Pain Syndrome

Interventions

Modified Bier block group:On the basis of conventional drug treatment, an improved Bier block method is adopted.
Pharmacological treatment group:First-line pharmacotherapy for neuropathic pain includes pregabalin at 150–300 mg per day. If pain relief is inadequate, tramadol is added.

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria for upper-limb CRPS (Budapest Criteria, revised 2010; 2. Age 18–65 years, regardless of sex; 3. Pain intensity VAS score >= 5; 4. CRPS duration > 3 months; 5. Voluntary participation, with informed consent signed by the patient and family members.

Exclusion criteria

Exclusion criteria: 1. Patients who have received neuromodulation treatments such as spinal cord stimulation or radiofrequency thermocoagulation; 2. Patients who have undergone nerve blocks within the past 3 months; 3. Known allergy to lidocaine, methylprednisolone, or mecobalamin; 4. Patients with moderate to severe pain in other body regions; 5. Patients with impaired upper-limb vascular circulation or coagulation disorders; 6. Patients with severe cardiac, pulmonary, hepatic, or renal disease, severe psychiatric disorders, or progressive malignant tumors; 7. Patients currently participating in other clinical trials involving investigational (unapproved) drugs or blinded clinical trials.

Design outcomes

Primary

MeasureTime frame
Brief Pain Inventory (BPI) ;

Secondary

MeasureTime frame
Fugl-Meyer Assessment (FMA) for upper extremity motor function;Sympathetic skin response (SSR);Temperature difference in the painful area.;Patients’Global Impressions of Change (PGIC);Short Form-36 Health Survey;Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS);Pittsburgh Sleep Quality Index (PSQI);

Countries

China

Contacts

Public ContactZheng Bixin

West China Hospital, Sichuan University

bixin.zheng@scu.edu.cn+86 187 1579 6522

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026